Poulvac Procerta HVT-IBD-ND (--) Concentrate and solvent for suspension for injection

Authorised

- Turkey herpesvirus, strain HVT-IBD-ND (cell-associated), expressing VP2 protein gene of Infectious bursal disease virus and fusion protein gene of Newcastle disease virus, Live

Product identification

Medicine name:
Poulvac Procerta HVT-IBD-ND (--) Concentrate and solvent for suspension for injection

Active substance:
Turkey herpesvirus, strain HVT-IBD-ND (cell-associated), expressing VP2 protein gene of Infectious bursal disease virus and fusion protein gene of Newcastle disease virus, Live

Target species:
Chicken
Chicken (embryonated eggs)

Route of administration:
In ovo
Subcutaneous use

Product details

Active substance and strength:
Turkey herpesvirus, strain HVT-IBD-ND (cell-associated), expressing VP2 protein gene of Infectious bursal disease virus and fusion protein gene of Newcastle disease virus, Live
3558.00 plaque forming unit / 1.00 Ampoule

Pharmaceutical form:
Concentrate and solvent for suspension for injection

Withdrawal period by route of administration:
In ovo:

- **Chicken**
  - All relevant tissues. 0 day — Zero days
- **Chicken (embryonated eggs)**
  - All relevant tissues. 0 day — Zero days

Subcutaneous use:

- **Chicken**
  - All relevant tissues. 0 day — Zero days
- **Chicken (embryonated eggs)**
  - All relevant tissues. 0 day — Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AD16

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:
Packaging:ampoule (glass), Package_size:1 ampoule, Content:4000 doses
Packaging:ampoule (glass), Package_size:1 ampoule, Content:2000 doses

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - known active substance (Article 8 of Regulation (EU) 2019/6)

Marketing authorisation holder:
Zoetis Belgium

Marketing authorisation date:
23/01/2025

Manufacturing sites for batch release:
Zoetis Manufacturing & Research Spain S.L.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
23/01/2025

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 7/05/2025
Download

ema-puar-v6306-poulvacprocertahvtibdnd-initial-en.pdf